The PIRO (predisposition, insult, response, organ dysfunction) model: Toward a staging system for acute illness

Virulence

Volumn 5, Issue 1, 2014, Pages 27-35

  Marshall, John C ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical trials; Critical illness; Epidemiology; Sepsis; Staging; Stratification

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 6; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ACUTE DISEASE; APACHE; CANCER STAGING; CLINICAL TRIAL (TOPIC); DATA BASE; DISEASE COURSE; DISEASE PREDISPOSITION; HEREDITY; HUMAN; HYPOXEMIA; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIPLE ORGAN FAILURE; NEOPLASM; NONHUMAN; PROGNOSIS; REVIEW; SEPSIS; STREPTOCOCCUS PNEUMONIA;

CLINICAL TRIALS; CRITICAL ILLNESS; EPIDEMIOLOGY; SEPSIS; STAGING; STRATIFICATION;

ACUTE DISEASE; CRITICAL ILLNESS; HUMANS; NEOPLASM STAGING; NEOPLASMS; SEPSIS;

EID: 84891657244     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.26908     Document Type: Review

References (64)

1. Williams GR. Presidential Address: a history of appendicitis. With anecdotes illustrating its importance. Ann Surg 1983; 197:495-506; PMID:6342553; http://dx.doi.org/10.1097/00000658-198305000-00001
2. Hansson J, Körner U, Khorram-Manesh A, Solberg A, Lundholm K. Randomized clinical trial of antibiotic therapy versus appendicectomy as primary treatment of acute appendicitis in unselected patients. Br J Surg 2009; 96:473-81; PMID:19358184; http://dx.doi.org/10.1002/bjs.6482
3. Shindoh J, Niwa H, Kawai K, Ohata K, Ishihara Y, Takabayashi N, Kobayashi R, Hiramatsu T. Diagnostic power of inflammatory markers in predicting severity of appendicitis. Hepatogastroenterology 2011; 58:2003-6; PMID:22234068
4. Gospodarowicz M, Benedet L, Hutter RV, Fleming I, Henson DE, Sobin LH. History and international developments in cancer staging. Cancer Prev Control 1998; 2:262-8; PMID:10470455
5. Sobin LH. TNM: evolution and relation to other prognostic factors. Semin Surg Oncol 2003; 21:3-7; PMID:12923909; http://dx.doi.org/10.1002/ssu.10014
6. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012; 488:49-56; PMID:22832581; http://dx.doi.org/10.1038/nature11327
7. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-57; PMID:12867608; http://dx.doi.org/10.1056/NEJMoa022289
8. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19:619-25; PMID:23584089; http://dx.doi.org/10.1038/nm.3175
9. Marshall JC, Sweeney D. Microbial infection and the septic response in critical surgical illness. Sepsis, not infection, determines outcome. Arch Surg 1990; 125:17-22, discussion 22-3; PMID:2294878; http://dx.doi.org/10.1001/archsurg.1990.01410130019002
10. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-52; PMID:7587228; http://dx.doi.org/10.1097/00003246-199510000-00007
11. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530-8; PMID:12664219; http://dx.doi.org/10.1007/s00134-003-1662-x
12. Sørensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318:727-32; PMID:3347221; http://dx.doi.org/10.1056/NEJM198803243181202
13. Barreiro LB, Quintana-Murci L. From evolutionary genetics to human immunology: how selection shapes host defence genes. Nat Rev Genet 2010; 11:17-30; PMID:19953080; http://dx.doi.org/10.1038/nrg2698
14. López C, Saravia C, Gomez A, Hoebeke J, Patarroyo MA. Mechanisms of genetically-based resistance to malaria. Gene 2010; 467:1-12; PMID:20655368; http://dx.doi.org/10.1016/j.gene.2010.07.008
15. Chapman SJ, Hill AV. Human genetic susceptibility to infectious disease. Nat Rev Genet 2012; 13:175-88; PMID:22310894
16. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, Frodsham AJ, Walley AJ, Kyrieleis O, Khan A, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39:523-8; PMID:17322885; http://dx.doi.org/10.1038/ng1976
17. Khor CC, Vannberg FO, Chapman SJ, Guo H, Wong SH, Walley AJ, Vukcevic D, Rautanen A, Mills TC, Chang KC, et al. CISH and susceptibility to infectious diseases. N Engl J Med 2010; 362:2092-101; PMID:20484391; http://dx.doi.org/10.1056/NEJMoa0905606
18. Mira J-P, Cariou A, Grall F, Delclaux C, Losser M-R, Heshmati F, Cheval C, Monchi M, Teboul JL, Riché F, et al. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282:561-8; PMID:10450718; http://dx.doi.org/10.1001/jama.282.6.561
19. Nakada TA, Russell JA, Boyd JH, Walley KR. IL17A genetic variation is associated with altered susceptibility to Gram-positive infection and mortality of severe sepsis. Crit Care 2011; 15:R254; PMID:22026963; http://dx.doi.org/10.1186/cc10515
20. Thair SA, Walley KR, Nakada TA, McConechy MK, Boyd JH, Wellman H, Russell JA. A single nucleotide polymorphism in NF-κB inducing kinase is associated with mortality in septic shock. J Immunol 2011; 186:2321-8; PMID:21257964; http://dx.doi.org/10.4049/jimmunol.1002864
21. Thompson CM, Holden TD, Rona G, Laxmanan B, Black RA, O'Keefe GE, Wurfel MM. Toll-Like Receptor 1 Polymorphisms and Associated Outcomes in Sepsis After Traumatic Injury: A Candidate Gene Association Study. Ann Surg 2013; (Forthcoming); PMID:23478521; http://dx.doi.org/10.1097/SLA.0b013e31828538e8
22. Zeng L, Gu W, Zhang AQ, Zhang M, Zhang LY, Du DY, Huang SN, Jiang JX. A functional variant of lipopolysaccharide binding protein predisposes to sepsis and organ dysfunction in patients with major trauma. Ann Surg 2012; 255:147-57; PMID:22167001; http://dx.doi.org/10.1097/SLA.0b013e3182389515
23. Zhao Y, Tao L, Jiang D, Chen X, Li P, Ning Y, Xiong R, Liu P, Peng Y, Zhou YG. The -144C/A polymorphism in the promoter of HSP90beta is associated with multiple organ dysfunction scores. PLoS One 2013; 8:e58646; PMID:23516526; http://dx.doi.org/10.1371/journal.pone.0058646
24. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-54; PMID:12700374; http://dx.doi.org/10.1056/NEJMoa022139
25. Sakr Y, Elia C, Mascia L, Barberis B, Cardellino S, Livigni S, Fiore G, Filippini C, Ranieri VM. The influence of gender on the epidemiology of and outcome from severe sepsis. Crit Care 2013; 17:R50; PMID:23506971; http://dx.doi.org/10.1186/cc12570
26. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Occurrence and outcomes of sepsis: influence of race. Crit Care Med 2007; 35:763-8; PMID:17255870; http://dx.doi.org/10.1097/01.CCM.0000256726.80998.BF
27. Pietropaoli AP, Glance LG, Oakes D, Fisher SG. Gender differences in mortality in patients with severe sepsis or septic shock. Gend Med 2010; 7:422-37; PMID:21056869; http://dx.doi.org/10.1016/j.genm.2010.09.005
28. Baker MG, Barnard LT, Kvalsvig A, Verrall A, Zhang J, Keall M, Wilson N, Wall T, Howden-Chapman P. Increasing incidence of serious infectious diseases and inequalities in New Zealand: a national epidemiological study. Lancet 2012; 379:1112-9; PMID:22353263; http://dx.doi.org/10.1016/S0140-6736(11)61780-7
29. Esper AM, Martin GS. The impact of comorbid [corrected] conditions on critical illness. Crit Care Med 2011; 39:2728-35; PMID:22094497; http://dx.doi.org/10.1097/CCM.0b013e318236f27e
30. Christiansen CF, Christensen S, Johansen MB, Larsen KM, Tønnesen E, Sørensen HT. The impact of pre-admission morbidity level on 3-year mortality after intensive care: a Danish cohort study. Acta Anaesthesiol Scand 2011; 55:962-70; PMID:21770901
31. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29; PMID:3928249; http://dx.doi.org/10.1097/00003246-198510000-00009
32. Metersky ML, Fine MJ, Mortensen EM. The effect of marital status on the presentation and outcomes of elderly male veterans hospitalized for pneumonia. Chest 2012; 142:982-7; PMID:22459780; http://dx.doi.org/10.1378/chest.11-3183
33. Frost DW, Cook DJ, Heyland DK, Fowler RA. Patient and healthcare professional factors influencing end-of-life decision-making during critical illness: a systematic review. Crit Care Med 2011; 39:1174-89; PMID:21336127; http://dx.doi.org/10.1097/CCM.0b013e31820eacf2
34. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 2010; 87:989-99; PMID:20179153; http://dx.doi.org/10.1189/jlb.1209775
35. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013; 110:3507-12; PMID:23401516; http://dx.doi.org/10.1073/pnas.1222878110
36. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, Hayden DL, Hennessy L, Moore EE, Minei JP, et al.; Inflammation and Host Response to Injury Large-Scale Collaborative Research Program. A genomic storm in critically injured humans. J Exp Med 2011; 208:2581-90; PMID:22110166; http://dx.doi.org/10.1084/jem.20111354
37. Lorente JA, Marshall JC. Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 2005; 24(Suppl 1):107-19; PMID:16374382; http://dx.doi.org/10.1097/01.shk.0000191343.21228.78
38. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, et al.; The XOMA Sepsis Study Group. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266:1097-102; PMID:1865542; http://dx.doi.org/10.1001/jama.1991.03470080067031
39. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, et al.; ACCESS Study Group. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013; 309:1154-62; PMID:23512062; http://dx.doi.org/10.1001/jama.2013.2194
40. Lee BH, Inui D, Suh GY, Kim JY, Kwon JY, Park J, Tada K, Tanaka K, Ietsugu K, Uehara K, et al.; Fever and Antipyretic in Critically ill patients Evaluation (FACE) Study Group. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Crit Care 2012; 16:R33; PMID:22373120; http://dx.doi.org/10.1186/cc11211
41. Marik PE, Zaloga GP. Hypothermia and cytokines in septic shock. Norasept II Study Investigators. North American study of the safety and efficacy of murine monoclonal antibody to tumor necrosis factor for the treatment of septic shock. Intensive Care Med 2000; 26:716-21; PMID:10945388; http://dx.doi.org/10.1007/s001340051237
42. Marshall JC, Reinhart K; International Sepsis Forum. Biomarkers of sepsis. Crit Care Med 2009; 37:2290-8; PMID:19487943; http://dx.doi.org/10.1097/CCM.0b013e3181a02afc
43. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010; 14:R15; PMID:20144219; http://dx.doi.org/10.1186/cc8872
44. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, et al.; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-82; PMID:15640628
45. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985; 1:16-9; PMID:2856949; http://dx.doi.org/10.1016/S0140-6736(85)90966-3
46. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72; PMID:16236737; http://dx.doi.org/10.1056/NEJMoa052306
47. Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998; 22:158-63; PMID:9451931; http://dx.doi.org/10.1007/s002689900364
48. Clec'h C, Timsit JF, De Lassence A, Azoulay E, Alberti C, Garrouste-Orgeas M, Mourvilier B, Troche G, Tafflet M, Tuil O, et al. Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med 2004; 30:1327-33; PMID:15197443; http://dx.doi.org/10.1007/s00134-004-2292-7
49. Bernard GR, Vincent J-L, Laterre PF, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709; PMID:11236773; http://dx.doi.org/10.1056/NEJM200103083441001
50. Moreno RP, Metnitz B, Adler L, Hoechtl A, Bauer P, Metnitz PG; SAPS 3 Investigators. Sepsis mortality prediction based on predisposition, infection and response. Intensive Care Med 2008; 34:496-504; PMID:18060541; http://dx.doi.org/10.1007/s00134-007-0943-1
51. Lisboa T, Diaz E, Sa-Borges M, Socias A, Sole-Violan J, Rodríguez A, Rello J. The ventilator-associated pneumonia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilatorassociated pneumonia. Chest 2008; 134:1208-16; PMID:18779186; http://dx.doi.org/10.1378/chest.08-1106
52. Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med 2009; 37:456-62; PMID:19114916; http://dx.doi.org/10.1097/CCM.0b013e318194b021
53. Rubulotta F, Marshall JC, Ramsay G, Nelson D, Levy M, Williams M. Predisposition, insult/infection, response, and organ dysfunction: A new model for staging severe sepsis. Crit Care Med 2009; 37:1329-35; PMID:19242329; http://dx.doi.org/10.1097/CCM.0b013e31819d5db1
54. Granja C, Póvoa P, Lobo C, Teixeira-Pinto A, Carneiro A, Costa-Pereira A. The predisposition, infection, response and organ failure (Piro) sepsis classification system: results of hospital mortality using a novel concept and methodological approach. PLoS One 2013; 8:e53885; PMID:23349756; http://dx.doi.org/10.1371/journal.pone.0053885
55. Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol 2008; 26:380-5; PMID:18202413; http://dx.doi.org/10.1200/JCO.2007.14.1291
56. Myburgh J, Cooper DJ, Finfer S, Bellomo R, Norton R, Bishop N, Kai Lo S, Vallance S; SAFE Study Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group; Australian Red Cross Blood Service; George Institute for International Health. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007; 357:874-84; PMID:17761591; http://dx.doi.org/10.1056/NEJMoa067514
57. Umicevic Mirkov M, Cui J, Vermeulen SH, Stahl EA, Toonen EJ, Makkinje RR, Lee AT, Huizinga TW, Allaart R, Barton A, et al. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis 2013; 72:1375-81; PMID:23233654; http://dx.doi.org/10.1136/annrheumdis-2012-202405
58. Endo S, Inada K, Yamada Y, Kasai T, Takakuwa T, Nakae H, Kikuchi M, Hoshi S, Suzuki M, Yamashita H, et al. Plasma tumour necrosis factor-alpha (TNF-alpha) levels in patients with burns. Burns 1993; 19:124-7; PMID:8471144; http://dx.doi.org/10.1016/0305-4179(93)90033-5
59. Roumen RMH, Hendriks T, van der Ven-Jongekrijg J, Nieuwenhuijzen GAP, Sauerwein RW, van der Meer JWM, Goris RJ. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993; 218:769-76; PMID:8257227; http://dx.doi.org/10.1097/00000658-199312000-00011
60. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012; 7:e30275; PMID:22272322; http://dx.doi.org/10.1371/journal.pone.0030275
61. D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 2010; 7:86-92; PMID:20134490; http://dx.doi.org/10.1038/nrgastro.2009.222
62. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013; 108:1268-76; PMID:23649185; http://dx.doi.org/10.1038/ajg.2013.138
63. Klein MB, Silver G, Gamelli RL, Gibran NS, Herndon DN, Hunt JL, Tompkins RG; Inflammation and the Host Response to Injury Investigators. Inflammation and the host response to injury: an overview of the multicenter study of the genomic and proteomic response to burn injury. J Burn Care Res 2006; 27:448-51; PMID:16819346; http://dx.doi.org/10.1097/01.BCR.0000227477.33877.E6
64. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Tugwell P. Developing core outcome sets for clinical trials: issues to consider. Trials 2012; 13:132; PMID:22867278; http://dx.doi.org/10.1186/1745-6215-13-132